about
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-...
Read More
8.72
0.10
(1.16%)
305.3K
XNAS Volume
XNAS 21 Sep, 2026 5:30 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Bearish
Weak Stock
These stocks have poor scores across the board. Investors should be very cautious with these stocks
View Similar
Embed DVM
Immatics N.V Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..